Both clinical studies established that Eroxon® met and exceeded the Minimal Clinically Important Difference “MCID” (Rosen et al 2011). The MCID is an outcome measure that would be noticeable to a person using the product and be of clinical relevance.
An overall MCID of a 4-unit change over baseline using the IIEF-EF (International Index of Erectile Function – an internationally recognized and fully validated standard used in ED clinical trials) is used by leading experts in ED and regulatory authorities as a threshold for success in ED clinical studies.
The information on this site is intended for consumers and healthcare professionals in the European Economic Area or the United Kingdom. Eroxon is not available in jurisdictions outside the European Economic Area or the United Kingdom. Users outside these jurisdictions,
please click here.